Phase 4
Completed N=833
Staph Household Intervention for Eradication (SHINE)
Skin and Subcutaneous Tissue Bacterial Infections · Staphylococcus aureus · MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Source: ClinicalTrials.gov NCT02572791 ↗
Enrolled (actual)
833
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcomePrimary: Number of Households With at Least One Skin and Soft Tissue Infection — 21; 21; 22 Households
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The investigators propose a pragmatic comparative effectiveness trial evaluating several decolonization strategies in patients with Staphylococcus aureus infection, their household contacts, and household environmental surfaces. The central hypothesis of this proposal is that an integrated approach of periodic personal and household environmental hygiene will reduce S. aureus transmission in households and subsequently decrease the incidence of skin and soft tissue infections (SSTI).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Households With at Least One Skin and Soft Tissue Infection |
21; 21; 22 | — |
| SECONDARY Prevalence of MRSA Colonization in Participants |
12; 22; 24 | — |
| SECONDARY Confirmed S. Aureus Infection |
84; 71; 135 | — |
| SECONDARY Incidence of SSTI |
30; 32; 38 | — |
| SECONDARY Mupirocin Resistance |
6; 1; 2 | — |
| SECONDARY Number of Patients With Adverse Events Due to Study Intervention |
111; 92; 137 | — |
| SECONDARY Number of Participants Adhering to Study Intervention Procedures |
112; 45; 55 | — |
| SECONDARY SSTI Incidence: Individual Level |
39; 31; 43 | — |
| SECONDARY SSTI Incidence: Participants With SSTI in the Year Prior to Trial Enrollment |
36; 40; 25 | — |
| SECONDARY SSTI Incidence: Index Patients |
23; 27; 16 | — |
Eligibility Criteria
Inclusion Criteria
- Patients 18 years of age and younger
- Confirmed (i.e., culture-positive) active or recent (within the past 2 months) S. aureus cutaneous infections
- Reside within 75 miles of St. Louis Children's Hospital
- Provide written, informed consent, or consent is provided by a parent or legal guardian
Exclusion Criteria
- Patients with nosocomial infections (i.e., >48 hours after hospitalization)
- Patients with traditional risk factors for HA-MRSA (e.g., immunodeficiency, indwelling catheter or percutaneous medical device, undergoing dialysis, presenting with a surgical site infection, or residing in a long-term care facility within the past year).
- Patients who are unable to give consent or for whom consent is not obtained
- Patients refusing home environmental cultures by the study team
- Patients without a permanent home (e.g., living in a shelter or group home)
Data sourced from ClinicalTrials.gov (NCT02572791). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.